Skip to Content
Merck
All Photos(1)

Documents

SML3285

Sigma-Aldrich

Apixaban

≥98% (HPLC), powder, Factor Xa (FXa) inhibitor

Synonym(s):

1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, BMS 562247, BMS-562247, BMS562247

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H25N5O4
CAS Number:
503612-47-3
Molecular Weight:
459.50
MDL number:
MFCD11977295
UNSPSC Code:
12352107
NACRES:
NA.77

product name

Apixaban, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

InChI key

QNZCBYKSOIHPEH-UHFFFAOYSA-N

Biochem/physiol Actions

Apixaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (human/rabbit Ki = 0.08/0.17 nM; trypsin Ki >3 μM) with good anticoagulant activity in vitro (EC2x = 3.8 μM by prothrombin time (PT) assay, 5.1 μM by activated partial thromboplastin time (aPTT) assay) and antithrombotic efficacy in vivo (IC50 = 329 nM i.v. by rabbit arteriovenous shunt model).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Noelle D Herrera et al.
Frontiers in veterinary science, 8, 702821-702821 (2021-07-23)
Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans. This study aimed to determine the pharmacokinetics (PK), bioactivity, protein binding, and bioavailability of
P C Wong et al.
Journal of thrombosis and haemostasis : JTH, 6(10), 1736-1741 (2008-07-24)
Optimal treatment of arterial thrombosis may include a combination of antiplatelet and anticoagulant drugs. We evaluated apixaban, a direct and highly selective factor Xa inhibitor, in combination with clinically relevant doses of aspirin and/or clopidogrel for prevention of arterial thrombosis
Donald J P Pinto et al.
Journal of medicinal chemistry, 50(22), 5339-5356 (2007-10-05)
Efforts to identify a suitable follow-on compound to razaxaban (compound 4) focused on modification of the carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline. Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained
P C Wong et al.
Journal of thrombosis and haemostasis : JTH, 6(5), 820-829 (2008-03-05)
Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases. We evaluated the in vitro properties of apixaban and its in vivo activities in rabbit models
P L A Giesen et al.
Thrombosis journal, 19(1), 60-60 (2021-08-30)
Thrombin generation (TG) assessed by Calibrated Automated Thrombogram (CAT-I) reflects the overall capacity of plasma to generate thrombin, thus evaluating the balance between the anti- and procoagulant processes. However, with this method the calibrator curve is usually not measured until

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service